[go: up one dir, main page]

MX2008002484A - Formulaciones de acetato de bazedoxifeno y proceso de fabricacion de los mismos. - Google Patents

Formulaciones de acetato de bazedoxifeno y proceso de fabricacion de los mismos.

Info

Publication number
MX2008002484A
MX2008002484A MX2008002484A MX2008002484A MX2008002484A MX 2008002484 A MX2008002484 A MX 2008002484A MX 2008002484 A MX2008002484 A MX 2008002484A MX 2008002484 A MX2008002484 A MX 2008002484A MX 2008002484 A MX2008002484 A MX 2008002484A
Authority
MX
Mexico
Prior art keywords
manufacturing process
bazedoxifene acetate
acetate formulations
formulations
bazedoxifene
Prior art date
Application number
MX2008002484A
Other languages
English (en)
Inventor
Syed M Shah
Eric C Ehrnsperger
Christopher R Diorio
Kadum A Ali
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37772333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2008002484(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2008002484A publication Critical patent/MX2008002484A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invencion esta dirigida a formulaciones de acetato de bazedoxifeno que tienen una conversion polimorfica reducida, a composiciones que las contienen, a sus preparaciones y sus usos.
MX2008002484A 2005-08-24 2006-08-23 Formulaciones de acetato de bazedoxifeno y proceso de fabricacion de los mismos. MX2008002484A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71076105P 2005-08-24 2005-08-24
PCT/US2006/032935 WO2007024961A2 (en) 2005-08-24 2006-08-23 Bazedoxifene acetate formulations and manufacturing process thereof

Publications (1)

Publication Number Publication Date
MX2008002484A true MX2008002484A (es) 2008-04-07

Family

ID=37772333

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008002484A MX2008002484A (es) 2005-08-24 2006-08-23 Formulaciones de acetato de bazedoxifeno y proceso de fabricacion de los mismos.

Country Status (21)

Country Link
US (1) US7771744B2 (es)
EP (1) EP1919456A2 (es)
JP (2) JP2009506053A (es)
KR (2) KR101584674B1 (es)
CN (1) CN101304731B (es)
AR (1) AR056471A1 (es)
AU (1) AU2006283121A1 (es)
BR (1) BRPI0615341A2 (es)
CA (1) CA2620174A1 (es)
CR (1) CR9746A (es)
EC (1) ECSP088214A (es)
GT (1) GT200600383A (es)
IL (2) IL189648A (es)
MX (1) MX2008002484A (es)
NO (1) NO20080991L (es)
PE (1) PE20070425A1 (es)
RU (1) RU2417084C2 (es)
SV (1) SV2008002825A (es)
TW (1) TW200738281A (es)
WO (1) WO2007024961A2 (es)
ZA (1) ZA200801742B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA86056C2 (ru) * 2004-04-08 2009-03-25 Уайет Твердый дисперсионный состав базедоксифена ацетата, способ его получения (варианты) и применение (варианты)
WO2007024961A2 (en) * 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof
CN101460150B (zh) * 2006-03-31 2014-02-12 鲁比康研究私人有限公司 用于口腔崩解片剂的可直接压片复合物
US20100092564A1 (en) * 2006-12-21 2010-04-15 Jae Han Park Composition of and Method for Preparing Orally Disintegrating Tablets
US20100016582A1 (en) * 2008-02-11 2010-01-21 Wyeth Methods of converting polymorphic form b of bazedoxifene acetate to polymorphic form a of bazedoxifene acetate
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
JP6093707B2 (ja) * 2010-11-30 2017-03-08 ウィスタ ラボラトリーズ リミテッド 化合物製剤
EP2471770A1 (en) * 2010-12-28 2012-07-04 Sandoz Ag Method of preparing polymorphic pure form A of bazedoxifene acetate
WO2013182169A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
WO2013182170A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate
CN103877581B (zh) * 2014-03-24 2016-03-02 江苏知原药业有限公司 一种性能优异的乙酸巴多昔芬缓释制剂
WO2018182205A1 (ko) * 2017-03-30 2018-10-04 한미약품 주식회사 바제독시펜 아세테이트를 함유하는 안정화된 약제학적 조성물
KR101940569B1 (ko) * 2017-05-24 2019-01-21 아주대학교산학협력단 바제독시펜 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물
CN112076163B (zh) * 2019-06-14 2023-06-20 四川科伦药物研究院有限公司 一种醋酸巴多昔芬片的药物组合物及其制备方法
CN111004165A (zh) * 2019-12-03 2020-04-14 南京正济医药研究有限公司 一种醋酸巴多昔芬晶型a的制备方法
CN112754999A (zh) * 2021-01-23 2021-05-07 郑州泰丰制药有限公司 一种醋酸巴多昔芬组合物及醋酸巴多昔芬薄膜衣片制备方法
CN113368075A (zh) * 2021-06-29 2021-09-10 郑州泰丰制药有限公司 一种醋酸巴多昔芬片及其制备方法
CA3229700A1 (en) * 2021-08-23 2023-03-02 Jan Brabek Treatment of covid-19

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686094A (en) * 1991-04-01 1997-11-11 Theratech, Inc. Controlled release formulations for the treatment of xerostomia
CA2224269C (en) * 1995-06-22 2008-06-17 Akzo Nobel N.V. Compressed dry-granulation desogestrel tablets
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
MXPA02007957A (es) 2000-02-17 2002-11-29 Amgen Inc Inhibidores de cinasas.
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
SG162615A1 (en) * 2002-06-13 2010-07-29 Wyeth Corp Bazedoxifene treatment regimens
CA2552725A1 (en) * 2004-01-13 2005-08-04 Wyeth Treatment of aromatase inhibitor therapy-related osteoporosis
CA2561296A1 (en) 2004-04-07 2005-10-27 Wyeth Crystalline polymorph of bazedoxifene acetate
TWI346105B (en) 2004-04-07 2011-08-01 Wyeth Corp Crystalline polymorph of bazedoxifene acetate
GT200500078A (es) * 2004-04-07 2005-10-31 Polimorfo cristalino de acetato de bazedoxifeno
UA86056C2 (ru) * 2004-04-08 2009-03-25 Уайет Твердый дисперсионный состав базедоксифена ацетата, способ его получения (варианты) и применение (варианты)
WO2007024961A2 (en) * 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof

Also Published As

Publication number Publication date
JP2013209419A (ja) 2013-10-10
BRPI0615341A2 (pt) 2011-05-17
CN101304731B (zh) 2012-06-20
IL233392A0 (en) 2014-08-31
RU2417084C2 (ru) 2011-04-27
WO2007024961A2 (en) 2007-03-01
WO2007024961A3 (en) 2007-06-28
SV2008002825A (es) 2008-06-30
EP1919456A2 (en) 2008-05-14
PE20070425A1 (es) 2007-07-02
CN101304731A (zh) 2008-11-12
KR20080043853A (ko) 2008-05-19
GT200600383A (es) 2007-03-29
IL189648A (en) 2014-07-31
AU2006283121A1 (en) 2007-03-01
RU2008107580A (ru) 2009-09-27
ECSP088214A (es) 2008-03-26
IL189648A0 (en) 2008-08-07
KR101584674B1 (ko) 2016-01-13
IL233392A (en) 2017-02-28
ZA200801742B (en) 2010-10-27
US7771744B2 (en) 2010-08-10
NO20080991L (no) 2008-05-15
CR9746A (es) 2008-08-21
JP2009506053A (ja) 2009-02-12
AR056471A1 (es) 2007-10-10
US20070048374A1 (en) 2007-03-01
CA2620174A1 (en) 2007-03-01
TW200738281A (en) 2007-10-16
KR20140088917A (ko) 2014-07-11

Similar Documents

Publication Publication Date Title
MX2008002484A (es) Formulaciones de acetato de bazedoxifeno y proceso de fabricacion de los mismos.
SG151331A1 (en) Crystalline polymorph of a bazedoxifene acetate
MX2009004746A (es) Derivados de 1,2,4-triazol como inhibidores del receptor sigma.
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
JO3181B1 (ar) مشتقات كمحول ثاني الكيل البايردينيل - أحادي الفينيل كأنزيم ثنائي استرات الفوسفود
PH12015501484A1 (en) Heteroaryl compounds and uses thereof
WO2007125103A3 (en) Benzamide glucokinase activators
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
JO2761B1 (en) Derivatives of alcohols 1-phenyl-2-pyridinealkyl as inhibitors
MY148634A (en) Pyridazinone derivatives
MX2008008152A (es) Compuestos heterociclicos biciclicos.
WO2006069363A3 (en) Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
UA86055C2 (ru) Кристаллическая форма в базедоксифена ацетата
TW200716568A (en) 1H-quinazoline-2,4-diones
TW200605863A (en) Bazedoxifene acetate formulations
WO2007072201A3 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
WO2010077730A3 (en) Indanone inhibitors of acetylcholinesterase
WO2007062338A3 (en) Solid formulations
WO2008033935A3 (en) Vinorelbine derivatives
UA85703C2 (en) Crystalline polymorph of bazedoxifene acetate
WO2006031929A3 (en) Thiazolopyridine kinase inhibitors
TNSN07462A1 (en) Ampa receptor potentiators
WO2006097809A3 (en) Novel tyrosine derivatives

Legal Events

Date Code Title Description
FG Grant or registration